Patient eligibility
The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with migalastat under the National Health Act 1953, section 85 for patients with Fabry disease.
Patients must be eligible for the PBS and meet the relevant restriction criteria.
The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing migalastat.
Treatment specifics
To be eligible for PBS-subsidised treatment with migalastat, patients must be treated by a physician with expertise in the management of Fabry disease.
Authority applications
Applying for initial treatment
Apply for initial authority approval to prescribe PBS-subsidised migalastat to treat Fabry disease in writing and either:
- use HPOS Form upload
- mail to PBS Complex Drugs Programs.
All written applications must include:
- details of the proposed prescription or prescriptions
- the completed Fabry disease - migalastat - initial authority application form
- relevant attachments.
Applying for initial grandfather treatment
For patients who received migalastat treatment or Enzyme Replacement Therapy under the Life Saving Drugs Program before 1 September 2024 for Fabry disease, apply for initial grandfather authority approval in writing and either:
- use HPOS Form upload
- mail to PBS Complex Drugs Programs.
All written applications must include:
- details of the proposed prescription or prescriptions
- the completed Fabry disease - migalastat - initial grandfather authority application form
- relevant attachments.
Applying for continuing treatment
Applications for continuing authority approval to prescribe PBS-subsided migalastat to treat Fabry disease can be made either:
- in real time using the Online PBS Authorities system
- by calling the PBS Complex Drugs Programs enquiry line.
More information
Call the PBS Complex Drugs Programs enquiry line for more information.